BR0208984A - ácidos graxos, glicerìdeos e análogos de comprimento de cadeia médio como fatores de sobrevivência e ativação de neutrófilos - Google Patents
ácidos graxos, glicerìdeos e análogos de comprimento de cadeia médio como fatores de sobrevivência e ativação de neutrófilosInfo
- Publication number
- BR0208984A BR0208984A BR0208984-0A BR0208984A BR0208984A BR 0208984 A BR0208984 A BR 0208984A BR 0208984 A BR0208984 A BR 0208984A BR 0208984 A BR0208984 A BR 0208984A
- Authority
- BR
- Brazil
- Prior art keywords
- medium chain
- survival
- fatty acids
- glycerides
- analogues
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7024—Esters of saccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2086—IL-13 to IL-16
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/18—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/47—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C235/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C235/08—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11C—FATTY ACIDS FROM FATS, OILS OR WAXES; CANDLES; FATS, OILS OR FATTY ACIDS BY CHEMICAL MODIFICATION OF FATS, OILS, OR FATTY ACIDS OBTAINED THEREFROM
- C11C3/00—Fats, oils, or fatty acids by chemical modification of fats, oils, or fatty acids obtained therefrom
- C11C3/003—Fats, oils, or fatty acids by chemical modification of fats, oils, or fatty acids obtained therefrom by esterification of fatty acids with alcohols
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11C—FATTY ACIDS FROM FATS, OILS OR WAXES; CANDLES; FATS, OILS OR FATTY ACIDS BY CHEMICAL MODIFICATION OF FATS, OILS, OR FATTY ACIDS OBTAINED THEREFROM
- C11C3/00—Fats, oils, or fatty acids by chemical modification of fats, oils, or fatty acids obtained therefrom
- C11C3/02—Fats, oils, or fatty acids by chemical modification of fats, oils, or fatty acids obtained therefrom by esterification of fatty acids with glycerol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/11—Compounds covalently bound to a solid support
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Wood Science & Technology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Communicable Diseases (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
"áCIDOS GRAXOS, GLICERìDEOS E ANáLOGOS DE COMPRIMENTO DE CADEIA MéDIO COMO FATORES DE SOBREVIVêNCIA E ATIVAçãO DE NEUTRóFILOS". Uma composição e um método para promover a sobrevivência e ativação de neutrófilos, tal como o tratamento de neutropenia, que surge como um efeito colateral indesejável da quimioterapia e da terapia por radiação. Uma composição contendo ácidos graxos de cadeia média, tais como ácido cáprico ou ácido caprílico, ou sais ou triglicerídeos dos mesmos, ou mono ou diglicerídeos, ou outros análogos dos mesmos, ou triglicerídeos de cadeia média (MCT), é administrada a um ser humano ou animal que necessite tratamento, em uma quantidade suficiente para reduzir ou eliminar a neutropenia. A composição é administrada em uma quantidade eficaz para tratar o distúrbio. Os métodos são também úteis para o gerenciamento de transplantes de medula óssea e no tratamento de várias doenças neutropênicas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US28445801P | 2001-04-18 | 2001-04-18 | |
PCT/CA2002/000535 WO2002083120A2 (en) | 2001-04-18 | 2002-04-18 | Medium-chain length fatty acids, glycerides and analogues as neutrophil survival and activation factors |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0208984A true BR0208984A (pt) | 2004-06-29 |
Family
ID=23090294
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0208984-0A BR0208984A (pt) | 2001-04-18 | 2002-04-18 | ácidos graxos, glicerìdeos e análogos de comprimento de cadeia médio como fatores de sobrevivência e ativação de neutrófilos |
Country Status (30)
Country | Link |
---|---|
US (2) | US7745488B2 (pt) |
EP (2) | EP1900364B1 (pt) |
JP (3) | JP5026655B2 (pt) |
KR (1) | KR20030096323A (pt) |
CN (1) | CN1633286A (pt) |
AP (1) | AP1740A (pt) |
AU (2) | AU2002308456B2 (pt) |
BG (1) | BG66418B1 (pt) |
BR (1) | BR0208984A (pt) |
CA (2) | CA2444463C (pt) |
CY (1) | CY1107081T1 (pt) |
CZ (1) | CZ305273B6 (pt) |
DE (1) | DE60223670T2 (pt) |
DK (2) | DK1385498T3 (pt) |
EA (1) | EA007322B1 (pt) |
EE (1) | EE200300510A (pt) |
ES (2) | ES2295397T3 (pt) |
HU (1) | HUP0303817A3 (pt) |
IL (3) | IL158322A0 (pt) |
MX (1) | MXPA03009436A (pt) |
NO (1) | NO335105B1 (pt) |
NZ (2) | NZ528690A (pt) |
OA (1) | OA12506A (pt) |
PL (2) | PL223348B1 (pt) |
PT (2) | PT1385498E (pt) |
SI (1) | SI1385498T1 (pt) |
SK (1) | SK12772003A3 (pt) |
TN (1) | TNSN03089A1 (pt) |
WO (1) | WO2002083120A2 (pt) |
ZA (1) | ZA200307778B (pt) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
OA12506A (en) * | 2001-04-18 | 2006-05-29 | Prometic Biosciences Inc | Medium-chain length fatty acids, glycerides and analogues as neutrophil survival and activation factors. |
AU2004210193B2 (en) * | 2003-02-07 | 2007-07-12 | Prometic Pharma Smt Limited | Medium-chain length fatty acids, glycerides and analogues as stimulators of erythropoiesis |
KR101120813B1 (ko) | 2003-07-25 | 2012-03-23 | 프로메틱 바이오사이언시즈 인코포레이티드 | 중-쇄 지방산 금속염의 제조 방법 |
US20070219131A1 (en) * | 2004-04-15 | 2007-09-20 | Ben-Sasson Shmuel A | Compositions capable of facilitating penetration across a biological barrier |
AU2005329255B2 (en) * | 2004-04-15 | 2010-09-30 | Chiasma, Inc. | Compositions capable of facilitating penetration across a biological barrier |
JP2008511553A (ja) * | 2004-09-03 | 2008-04-17 | プロメティック バイオサイエンシズ インコーポレーテッド | 免疫調節活性および化学防護活性を有する置換型プリニル誘導体ならびにその単独使用または中鎖長の脂肪酸もしくはグリセリドとの併用 |
US8071580B2 (en) | 2004-10-01 | 2011-12-06 | Prometic Biosciences Inc. | Medium-chain length fatty alcohols as stimulators of hematopoiesis |
BRPI0516827A (pt) * | 2004-10-01 | 2008-09-23 | Prometic Biosciences Inc | alcoóis graxos de comprimento de cadeia médio como estimuladores de hematopoese |
ATE553114T1 (de) * | 2005-02-28 | 2012-04-15 | Alphabeta Ab | Verbindungen zur verminderung der aggregation von amyloid-beta-peptid |
WO2007136424A2 (en) * | 2006-05-17 | 2007-11-29 | Cognate Therapeutics, Inc. | Isolation and purification of hematopoietic stem cells from post-liposuction lipoaspirates |
DK2180787T3 (da) | 2007-08-01 | 2014-02-03 | Univ Pittsburgh | Nitrooliesyremodulering af type ii-diabetes |
MY151439A (en) * | 2007-11-02 | 2014-05-30 | Prometic Biosciences Inc | Medium-chain length fatty acids and glycerides as nephroprotection agents |
TWI448290B (zh) * | 2007-12-19 | 2014-08-11 | Prometic Biosciences Inc | 與健擇他濱(gemcitabine)組合用於胰臟癌之治療的中等鏈長脂肪酸、鹽類及三酸甘油酯 |
CA2729053A1 (en) | 2008-05-01 | 2009-11-05 | Bruce A. Freeman | Vinyl substituted fatty acids |
CN102099024B (zh) * | 2008-06-19 | 2015-11-25 | 犹他大学研究基金会 | 硝化脂质在毒性医疗疗法的副作用的治疗上的用途 |
US20140024713A1 (en) | 2008-06-19 | 2014-01-23 | University Of Utah Research Foundation | Use of nitrated lipids for treatment of side effects of toxic medical therapies |
MX2011002836A (es) | 2008-09-17 | 2011-04-28 | Chiasma Inc | Composiciones farmaceúticas y métodos de administración relacionados. |
EP2165713B1 (en) * | 2008-09-19 | 2012-11-14 | Nestec S.A. | Whey and thymus function |
EP3045167A1 (en) | 2009-07-31 | 2016-07-20 | University of Pittsburgh - Of the Commonwealth System of Higher Education | Keto fatty acids as anti-inflammatory agents |
WO2011041639A2 (en) | 2009-10-02 | 2011-04-07 | Miller Raymond A | Heteroatom containing substituted fatty acids |
EP2394636B1 (en) * | 2010-05-28 | 2014-03-19 | Novagali Pharma S.A. | Method for treating retinal conditions using an intraocular tamponade |
EP2744491B1 (en) | 2011-08-19 | 2020-07-29 | The University of Utah Research Foundation | Combination therapy with nitrated lipids and inhibitors of the renin-angiotensin-aldosterone system |
TWI572352B (zh) * | 2012-03-01 | 2017-03-01 | 波麥堤克藥學Smt有限公司 | 用於製備具中鏈長度之脂肪酸的三酸甘油酯之方法 |
DK2846809T3 (da) | 2012-05-09 | 2021-01-18 | Cantex Pharmaceuticals Inc | Behandling af myelosuppression |
US20160199338A1 (en) | 2013-08-19 | 2016-07-14 | Enzychem Lifesciences Corporation | Compositions containing monoacetyldiacylglycerol compound as an active ingredient for preventing or treating rheumatoid arthritis |
CN106535887A (zh) | 2014-05-15 | 2017-03-22 | 株式会社Enzychem生命科学 | 治疗白细胞减少症和血小板减少症的方法 |
MA41462A (fr) | 2015-02-03 | 2021-05-12 | Chiasma Inc | Méthode de traitement de maladies |
WO2016133910A1 (en) | 2015-02-17 | 2016-08-25 | Cantex Pharmaceuticals, Inc. | Treatment of cancers and hematopoietic stem cell disorders privileged by cxcl12-cxcr4 interaction |
AU2016289856B2 (en) | 2015-07-07 | 2020-11-26 | H. Lundbeck A/S | PDE9 inhibitors with imidazo triazinone backbone and imidazo pyrazinone backbone for treatment of peripheral diseases |
EP3355879A4 (en) | 2015-10-02 | 2019-05-22 | Complexa, Inc. | PREVENTION, TREATMENT AND INVERSION OF DISEASE USING THERAPEUTICALLY EFFECTIVE AMOUNTS OF ACTIVATED FATTY ACIDS |
US9808438B2 (en) * | 2015-11-09 | 2017-11-07 | Enzychem Lifesciences Corporation | Method for treating mucositis |
WO2017185038A1 (en) | 2016-04-22 | 2017-10-26 | Receptor Life Sciences | Fast-acting plant-based medicinal compounds and nutritional supplements |
WO2017211274A1 (en) | 2016-06-08 | 2017-12-14 | Dong Yuhong | Lipids with odd number of carbon atoms and their use as pharmaceutical composition or nutritional supplement |
EA201892396A1 (ru) | 2016-12-02 | 2019-04-30 | Ресептор Лайф Сайенсиз, Инк. | Быстродействующие растительные лекарственные соединения и биологически активные добавки |
CN107382710B (zh) * | 2017-08-19 | 2020-11-06 | 中国铁道科学研究院集团有限公司铁道建筑研究所 | 一种接枝抗氧剂分子的多元醇 |
WO2019052629A1 (en) * | 2017-09-12 | 2019-03-21 | Sunregen Healthcare Ag | LIPIDS HAVING AN IMPERATIVE NUMBER OF CARBON ATOMS AND THEIR USE AS A PHARMACEUTICAL COMPOSITION OR FOOD SUPPLEMENT |
JP2020536858A (ja) * | 2017-10-05 | 2020-12-17 | レセプター・ホールディングス・インコーポレイテッド | 改善されたバイオアベイラビリティーを有するハーブ組成物 |
MX2020003573A (es) * | 2017-10-05 | 2020-08-03 | Receptor Holdings Inc | Formulaciones cannabinoides sinteticas y a base de plantas de inicio rapido y accion prolongada. |
KR102054401B1 (ko) * | 2018-03-26 | 2019-12-10 | 주식회사 엔지켐생명과학 | 1,2-디아실글리세롤 화합물, 그 제조방법 및 이를 유효성분으로 함유하는 면역조절제 |
SI3801526T1 (sl) | 2018-05-25 | 2024-05-31 | Cardurion Pharmaceuticals, Inc. | Monohidratne in kristalinične oblike 6-((3s, 4s)-4-metil-1-(pirimidin-2-ilmetil)pirolidin-3-il)-3-tetrahidropiran-4- il-7h-imidazo (1.5 - a) pirazin-8-ona |
CN114556680B (zh) * | 2019-10-31 | 2024-04-26 | 日本瑞翁株式会社 | 锂离子二次电池间隔件用功能层、带有锂离子二次电池间隔件用功能层的间隔件、锂离子二次电池、以及它们的制造方法 |
US11141457B1 (en) | 2020-12-28 | 2021-10-12 | Amryt Endo, Inc. | Oral octreotide therapy and contraceptive methods |
KR20240089762A (ko) * | 2021-10-18 | 2024-06-20 | 주식회사 엔지켐생명과학 | 점막염 치료용 조성물 및 방법 |
WO2023205196A1 (en) * | 2022-04-21 | 2023-10-26 | Merck Sharp & Dohme Llc | Process for preparing agglomerated crystalline medium-chain fatty acid sodium salts |
Family Cites Families (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2006A (en) * | 1841-03-16 | Clamp for crimping leather | ||
US2003A (en) * | 1841-03-12 | Improvement in horizontal windivhlls | ||
US2008A (en) * | 1841-03-18 | Gas-lamp eok conducting gas pkom ah elevated buhner to one below it | ||
US2004A (en) * | 1841-03-12 | Improvement in the manner of constructing and propelling steam-vessels | ||
US2002A (en) * | 1841-03-12 | Tor and planter for plowing | ||
US4528197A (en) * | 1983-01-26 | 1985-07-09 | Kabivitrum Ab | Controlled triglyceride nutrition for hypercatabolic mammals |
US4703062A (en) * | 1984-01-16 | 1987-10-27 | Baxter Travenol Laboratories, Inc. | Parenteral nutrition with medium and long chain triglycerides |
US4871768A (en) * | 1984-07-12 | 1989-10-03 | New England Deaconess Hospital Corporation | Dietary supplement utilizing ω-3/medium chain trigylceride mixtures |
US4816440A (en) * | 1985-09-26 | 1989-03-28 | Cetus Corporation | Stable formulation of biologically active proteins for parenteral injection |
US7307166B1 (en) * | 1987-10-28 | 2007-12-11 | Wellstat Therapeutics Corporation | Oxpurine nucleosides and their congeners, and acyl, derivatives thereof, for improvement of hematopoiesis |
US5011852A (en) * | 1988-07-25 | 1991-04-30 | Applied Analytical Industries, Inc. | Liquid oral pharmaceutical compositions of non-steroidal anti-inflammatory drugs |
JPH02134326A (ja) * | 1988-11-14 | 1990-05-23 | Snow Brand Milk Prod Co Ltd | 高度侵襲用経腸栄養剤 |
JP3249147B2 (ja) * | 1990-06-01 | 2002-01-21 | キリン−アムジエン・インコーポレーテツド | 生理活性蛋白含有経口製剤 |
AU1462392A (en) * | 1991-02-22 | 1992-09-15 | Amgen, Inc. | Use of gm-csf and g-csf to promote accelerated wound healing |
JP3132085B2 (ja) * | 1991-09-06 | 2001-02-05 | ウェルファイド株式会社 | 脂肪乳剤 |
JPH05163160A (ja) * | 1991-12-13 | 1993-06-29 | Snow Brand Milk Prod Co Ltd | 免疫低下に伴う感染症の予防及び治療用栄養剤 |
US5214035A (en) * | 1992-04-16 | 1993-05-25 | Hoechst-Roussel Agri-Vet Company | Thixotropic formulations |
US5308832A (en) * | 1992-07-27 | 1994-05-03 | Abbott Laboratories | Nutritional product for persons having a neurological injury |
US5318781A (en) * | 1993-04-06 | 1994-06-07 | Hoffmann-La Roche Inc. | Absorption enhancement of antibiotics |
US20010003739A1 (en) * | 1993-06-24 | 2001-06-14 | Astrazeneca Ab | Systemic administration of a therapeutic preparation |
US5631219A (en) * | 1994-03-08 | 1997-05-20 | Somatogen, Inc. | Method of stimulating hematopoiesis with hemoglobin |
AU7082694A (en) * | 1994-05-10 | 1995-11-29 | Kitasato Institute, The | Hematopoietic stem cell proliferation accelerator |
US5470861A (en) * | 1994-08-04 | 1995-11-28 | Hoffmann-La Roche Inc. | Method of promoting hair growth |
US5549905A (en) * | 1994-10-18 | 1996-08-27 | Clintec Nutrition Co. | Enternal composition for pediatric patients |
JPH08208510A (ja) | 1994-11-03 | 1996-08-13 | F Hoffmann La Roche Ag | インターフェロン組成物 |
GB9516268D0 (en) * | 1995-08-08 | 1995-10-11 | Danbiosyst Uk | Compositiion for enhanced uptake of polar drugs from the colon |
US5733884A (en) * | 1995-11-07 | 1998-03-31 | Nestec Ltd. | Enteral formulation designed for optimized wound healing |
AU701736B2 (en) * | 1995-11-28 | 1999-02-04 | B. Braun Melsungen Ag | Hydrolysis-optimized lipid emulsions and use thereof |
AUPN933396A0 (en) * | 1996-04-17 | 1996-05-09 | Pfizer Pty Limited | Non-aqueuos oral-drench compositions containing avermectin compounds |
US5851534A (en) * | 1996-05-03 | 1998-12-22 | Dynagen, Inc. | Methods for prevention and/or treatment of neutropenia |
JPH10265380A (ja) | 1997-03-17 | 1998-10-06 | Bristol Myers Squibb Co | 抗ガン剤 |
US6017531A (en) * | 1997-06-02 | 2000-01-25 | W. R. Grace & Co. | Hydrophilic composition containing protease produced by Vibrio |
EP1009383A1 (en) | 1997-09-04 | 2000-06-21 | Biozone Laboratories, Inc. | Oral liposomal delivery system |
EP1032358B1 (en) * | 1997-11-19 | 2005-05-18 | Hercules Incorporated | Fluidized polymer suspensions of cationic polysaccharides in emollients and use thereof in preparing personal care compositions |
EP1061932B1 (en) * | 1997-11-20 | 2006-01-25 | Gil Ja Jhon | Pharmaceutical composition containing extracts of cervus nippon antlers having growth-stimulating activities of hematopoietic stem cells and megakaryocytes |
ATE246506T1 (de) | 1998-03-11 | 2003-08-15 | Grelan Pharmaceutical Co | Darmlösliche sprudelnde zusammensetzungen |
US6267985B1 (en) * | 1999-06-30 | 2001-07-31 | Lipocine Inc. | Clear oil-containing pharmaceutical compositions |
JP2003513019A (ja) * | 1999-09-27 | 2003-04-08 | ソーナス ファーマシューティカルス,インコーポレイテッド | トコール可溶性治療剤の組成物 |
US6835750B1 (en) * | 2000-05-01 | 2004-12-28 | Accera, Inc. | Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II |
DE60123603T2 (de) * | 2000-06-14 | 2007-08-16 | William Leslie Diss Porter | Lipide zur änderung des abwehrsystems |
CA2407896A1 (en) * | 2000-06-20 | 2001-12-27 | Nutrition Sciences | Medium chain fatty acids applicable as antimicrobial agents |
US6967028B2 (en) * | 2000-07-31 | 2005-11-22 | Mainelab | Prolonged release microspheres for injectable administration |
IL142535A0 (en) | 2001-04-11 | 2002-03-10 | Yeda Res & Dev | Pharmaceutical compositions for the treatment of inflammation |
OA12506A (en) * | 2001-04-18 | 2006-05-29 | Prometic Biosciences Inc | Medium-chain length fatty acids, glycerides and analogues as neutrophil survival and activation factors. |
US20040052836A1 (en) | 2002-09-13 | 2004-03-18 | Li Luk Chiu | Pharmaceutical compositions containing at least one stable liposphere having an improved shelf life |
AU2004210193B2 (en) | 2003-02-07 | 2007-07-12 | Prometic Pharma Smt Limited | Medium-chain length fatty acids, glycerides and analogues as stimulators of erythropoiesis |
US6725510B1 (en) * | 2003-04-25 | 2004-04-27 | Almetta Clyburn | Inclining coffin |
KR101120813B1 (ko) | 2003-07-25 | 2012-03-23 | 프로메틱 바이오사이언시즈 인코포레이티드 | 중-쇄 지방산 금속염의 제조 방법 |
JP2008511553A (ja) * | 2004-09-03 | 2008-04-17 | プロメティック バイオサイエンシズ インコーポレーテッド | 免疫調節活性および化学防護活性を有する置換型プリニル誘導体ならびにその単独使用または中鎖長の脂肪酸もしくはグリセリドとの併用 |
US8071580B2 (en) * | 2004-10-01 | 2011-12-06 | Prometic Biosciences Inc. | Medium-chain length fatty alcohols as stimulators of hematopoiesis |
-
2002
- 2002-04-18 OA OA1200300273A patent/OA12506A/en unknown
- 2002-04-18 NZ NZ528690A patent/NZ528690A/en not_active IP Right Cessation
- 2002-04-18 KR KR10-2003-7013555A patent/KR20030096323A/ko active Search and Examination
- 2002-04-18 US US10/475,266 patent/US7745488B2/en active Active
- 2002-04-18 CZ CZ2003-2685A patent/CZ305273B6/cs not_active IP Right Cessation
- 2002-04-18 EP EP07116425.5A patent/EP1900364B1/en not_active Expired - Lifetime
- 2002-04-18 EE EEP200300510A patent/EE200300510A/xx unknown
- 2002-04-18 CA CA2444463A patent/CA2444463C/en not_active Expired - Lifetime
- 2002-04-18 PL PL366435A patent/PL223348B1/pl unknown
- 2002-04-18 MX MXPA03009436A patent/MXPA03009436A/es active IP Right Grant
- 2002-04-18 HU HU0303817A patent/HUP0303817A3/hu unknown
- 2002-04-18 DK DK02761857T patent/DK1385498T3/da active
- 2002-04-18 ES ES02761857T patent/ES2295397T3/es not_active Expired - Lifetime
- 2002-04-18 SK SK1277-2003A patent/SK12772003A3/sk unknown
- 2002-04-18 BR BR0208984-0A patent/BR0208984A/pt not_active Application Discontinuation
- 2002-04-18 AU AU2002308456A patent/AU2002308456B2/en not_active Expired
- 2002-04-18 PL PL402948A patent/PL222876B1/pl unknown
- 2002-04-18 PT PT02761857T patent/PT1385498E/pt unknown
- 2002-04-18 EP EP02761857A patent/EP1385498B1/en not_active Expired - Lifetime
- 2002-04-18 ES ES07116425.5T patent/ES2439738T3/es not_active Expired - Lifetime
- 2002-04-18 SI SI200230655T patent/SI1385498T1/sl unknown
- 2002-04-18 IL IL15832202A patent/IL158322A0/xx active IP Right Grant
- 2002-04-18 DE DE60223670T patent/DE60223670T2/de not_active Expired - Lifetime
- 2002-04-18 CN CNA028094263A patent/CN1633286A/zh active Pending
- 2002-04-18 CA CA2763637A patent/CA2763637C/en not_active Expired - Lifetime
- 2002-04-18 PT PT71164255T patent/PT1900364E/pt unknown
- 2002-04-18 EA EA200301131A patent/EA007322B1/ru not_active IP Right Cessation
- 2002-04-18 JP JP2002580924A patent/JP5026655B2/ja not_active Expired - Lifetime
- 2002-04-18 NZ NZ541140A patent/NZ541140A/en not_active IP Right Cessation
- 2002-04-18 WO PCT/CA2002/000535 patent/WO2002083120A2/en active Application Filing
- 2002-04-18 DK DK07116425.5T patent/DK1900364T3/da active
- 2002-04-18 AP APAP/P/2003/002888A patent/AP1740A/en active
-
2003
- 2003-07-08 TN TNPCT/CA2002/000535A patent/TNSN03089A1/en unknown
- 2003-10-06 ZA ZA200307778A patent/ZA200307778B/en unknown
- 2003-10-09 IL IL158322A patent/IL158322A/en unknown
- 2003-10-17 BG BG108280A patent/BG66418B1/bg unknown
- 2003-10-17 NO NO20034644A patent/NO335105B1/no not_active IP Right Cessation
-
2006
- 2006-03-21 AU AU2006201163A patent/AU2006201163B2/en not_active Expired
-
2007
- 2007-12-12 CY CY20071101574T patent/CY1107081T1/el unknown
-
2008
- 2008-11-10 IL IL195200A patent/IL195200A/en active IP Right Grant
-
2009
- 2009-11-30 JP JP2009272679A patent/JP5657879B2/ja not_active Expired - Lifetime
-
2010
- 2010-06-11 US US12/814,028 patent/US8487001B2/en not_active Expired - Lifetime
-
2014
- 2014-08-15 JP JP2014165557A patent/JP6420089B2/ja not_active Expired - Lifetime
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0208984A (pt) | ácidos graxos, glicerìdeos e análogos de comprimento de cadeia médio como fatores de sobrevivência e ativação de neutrófilos | |
BR0214772A (pt) | sistemas e métodos para o tratamento de pacientes com células lipoaspiradas processadas | |
BR0110420A (pt) | Agonistas muscarìnicos | |
BRPI0414455A (pt) | métodos para usar células regenerativas no tratamento de doença vascular periférica e distúrbios afins | |
MD960307A (ro) | Compoziţii farmaceutice cu conţinut de acid hialuronic, utilizarea compoziţiilor pentru tratamentul bolilor pielii, metodă de tratament al bolilor pielii | |
DE69215722T3 (de) | Verstärker zur Ultraschalltherapie von Erkrankungen sowie diesen enthaltende flüssige Arzneimittelzusammensetzungen | |
BR9911076A (pt) | Uso de peg-ifn-alfa e ribavirina para o tratamento de hepatite c crÈnica | |
ES2179319T3 (es) | Acido linoleico conjugado para mantener o aumentar el contenido de minerales de los huesos. | |
BR9715022A (pt) | Método para tratar de doenças prostáticas usando formulações de vitamina d por liberação sistemática e/ou prolongada | |
ATE282425T1 (de) | Verfahren zur behandlung von endothelialen verletzungen | |
BR0014166A (pt) | Método de utilização de inibidores de reabsorção de serotonina seletivo de rápido ataque para tratamento de disfunção sexual | |
EP1100507A4 (en) | ANTIOXIDANT COMPOSITION AND USE THEREOF FOR THE TREATMENT OF CONDITIONS | |
IL138290A0 (en) | Use of selegiline or desmethylselegiline for treating wounds, burns and dermatological damage | |
Nordgaard et al. | Influence of submucous septal resection on facial growth in the rat | |
BR0311371A (pt) | Composições para uso terapêutico compreendendo uma vitamina, um sal de metal e insulina ou um hormÈnio de crescimento | |
AR045263A1 (es) | Metodo, kit y composicion farmaceutica para tratar infecciones virales | |
BR0110396A (pt) | Métodos para prevenir e tratar alopecia induzida por quimioterapia ou radioterapia | |
MX9304925A (es) | Composiciones terapeuticas contra el cancer para profilaxis o para el tratamiento de cancer. | |
Kireev et al. | The effect of antioxidants on the microstructure of tissues in the experimental aseptic inflammation focus | |
ES2031462T3 (es) | Procedimiento para producir 1-b-d-arabinofuranosilcitosina-5'-estearilfosfato monosodico y monohidrato de la misma, y compuesto farmaceutico que contiene esta ultima. | |
Shih et al. | Effect of prostaglandin E, on the periosteal regional acceleratory phenomenon in fractured ribs: Histomorphometric study in Beagles | |
HUT62474A (en) | Process for producing veterinary composition with antiparasitic effect | |
RU2235548C1 (ru) | Ранозаживляющее средство | |
ATE91079T1 (de) | Salicylsaeurehaltiges mittel gegen schuppende hauterkrankungen. | |
Shrivastava et al. | Biochemical alterations in healing tissues with herbal preparations in cow calves |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B15K | Others concerning applications: alteration of classification |
Free format text: PARA.INT.CI. A61K 31/20, A61K 31/19, A61K 31/195, A61K 31/23, A61K 31/255, A61P 7/00, C07C 233/18, C07C 233/47, C07C 69/025, C07C 69/30 Ipc: A61K 31/20 (2006.01), A61K 31/23 (2006.01), A61K 3 |
|
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] | ||
B12B | Appeal against refusal [chapter 12.2 patent gazette] | ||
B25A | Requested transfer of rights approved |
Owner name: PROMETIC PHARMA SMT LIMITED (CA) |